Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 46 Sarcoma 21 Neoplasms 18 Neoplasm Metastasis 15 Ovarian Neoplasms 12 Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 8 Recurrence 5 Melanoma 5 Fallopian Tube Neoplasms 5 Thyroid Neoplasms 4 Prostatic Neoplasms 4 Liposarcoma 4 Hemangiosarcoma 4 Urinary Bladder Neoplasms 3 Solid Tumors 3 Lung Neoplasms 3 Leiomyosarcoma 3 Kidney Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Carcinoma, Ovarian Epithelial 3 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Synovial 2 Refractory Solid Tumors 2 Neuroendocrine Tumors 2 Gliosarcoma 2 Financial Stress 2 Chondrosarcoma, Extraskeletal Myxoid 2

Interventions

vandetanib 1 pazopanib 1 Surgical Procedures, Operative 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × GIST × pazopanib × Clear all

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡